The main side effects that are common for anti-IL-17 mAbs include infectious complications, allergic reactions, hematological changes, liver enzyme elevation, etc. In contrast to anti-TNFα therapeutic means, IL-17 inhibitors showed a better safety profile regarding tuberculosis. This evidence concerns the gene IL17A and tuberculosis.